Nitroprussid-Natrium Aftpharm (Sodium Nitroprusside)

Sodium Nitroprusside, the active ingredient in Nitroprussid‑Natrium, is a direct‑acting vasodilator presented as an injectable solution for intravenous use. It rapidly reduces arterial and venous pressure, making it valuable in acute hypertensive crises, controlled hypotension during surgery, and severe heart failure management.

GNH USA supplies Nitroprussid‑Natrium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The product complies with European Union pharmacopeial standards and is distributed under strict quality assurance protocols.

Sodium Nitroprusside is used in clinical situations that require rapid and controllable vasodilation.

Acute hypertensive crisis: rapid reduction of severe blood‑pressure elevations. Controlled hypotension during surgery: maintains target low arterial pressure to reduce intra‑operative bleeding. Severe heart failure: decreases preload and afterload to improve cardiac output.

Intravenous sodium nitroprusside may be associated with a range of adverse reactions.

Common Side Effects: - Headache: transient throbbing pain often related to rapid pressure drop. - Nausea: mild stomach upset that may accompany infusion. - Flushing: warm sensation and reddening of the skin. - Dizziness: feeling of light‑headedness due to lowered blood pressure. - Hypotension: excessive fall in blood pressure if infusion rate is too high. - Tachycardia: compensatory increase in heart rate.

Serious or Rare Side Effects: - Cyanide toxicity: accumulation of cyanide ions with prolonged high‑dose infusions. - Thiocyanate accumulation: can cause neurologic or thyroid disturbances. - Severe hypotension: profound blood‑pressure collapse requiring immediate intervention. - Methemoglobinemia: oxidation of hemoglobin impairing oxygen delivery. - Arrhythmias: irregular heart rhythms, including ventricular ectopy. - Renal dysfunction: impaired kidney function in susceptible patients.

When using sodium nitroprusside, careful clinical monitoring and risk assessment are essential. - Dose titration: adjust infusion rate to achieve the desired blood‑pressure target. - Continuous monitoring: observe arterial pressure and heart‑rate continuously. - Cyanide risk: limit infusion duration and monitor plasma cyanide levels in prolonged therapy. - Renal function: assess baseline and ongoing kidney function before and during treatment. - Thiocyanate accumulation: be vigilant in patients receiving therapy beyond 24 hours. - Store at below 25°C: keep in the original container, protect from light and moisture.

Sodium nitroprusside can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other vasodilators (e.g., nitroglycerin): additive hypotensive effect. - ACE inhibitors or ARBs: potentiate blood‑pressure reduction. - Beta‑blockers: may mask reflex tachycardia.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance volume depletion and hypotension. - Lithium: altered renal clearance can increase lithium toxicity. - Phenobarbital: may increase metabolic clearance of nitroprusside, reducing its effect.